Sanofi signs with IONTAS to discover antibodies using mammalian display tech

25-Jan-2018 - Last updated on 25-Jan-2018 at 14:05 GMT

(Image: IONTAS)

Sanofi and IONTAS have signed an agreement through which the company will use IONTAS’ proprietary technology – which aims to bridge the gap between a “great lead” and “poor developability,” says CBO.

IONTAS generates antibodies with favorable binding and expression properties using its Mammalian Display Antibody Discovery Platform, according to the UK-based company.

The platform enables the construction of monoclonal cell line libraries, which each display a different IgG-formatted antibody on the cell surface.

Commenting on the benefits of using Mammalian Display Technology to discover antibodies, Neil Butt, chief business officer (CBO) of IONTAS told us the application of mammalian display is an important step in integrating antibody discovery with CMC (chemistry, manufacturing, and controls) and manufacturing.

“The issue of developability in the biopharmaceutical industry has become a major issue of late and many R&D groups and manufacturing groups will be familiar with the identification of a great lead that subsequently is dropped due to poor developability,” Butt explained.

“The mammalian display technology aims to bridge this gap, thereby facilitate speedy progression of antibodies into the clinic,” he added.

Sanofi also recently established a partnership with TriNetX to reduce clinical trial complexity and speed development times.